Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 6/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 4/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 6/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382571 | 0.90 | SMARCA2 (0.38) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777883 | 0.90 | SMARCA2 (0.38) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777857 | 0.90 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777912 | 0.84 | BTK (0.37) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777839 | 0.82 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777874 | 0.82 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777871 | 0.82 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777907 | 0.82 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL22777902 | 0.82 | PBRM1 (0.38) | PBRM1SMARCA2SMARCA4BTKCAMKK2 | |
| SCHEMBL25468671 | 0.81 | PTPN11 (0.41) | BTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PBRM1 5/4885SMARCA2 6/4885SMARCA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.